Gilead/Achillion Advance Back-Up Anti-HCV Molecule After Toxicity Problems With Lead Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies plan IND filing for their next novel NS4A antagonist in the first or second quarter of 2008.